Author

Karen L. Fink

Observed names: K L Fink, Karen Fink, Karen L Fink

Institutions: Baylor College of Medicine, Baylor University Medical Center, Baylor Scott & White Health

Observed institutions: Mayo Clinic, The University of Texas at Dallas, Baylor College of Medicine, University of Washington, Baylor University Medical Center, Duke Medical Center, Baylor Scott & White Health, The University of Texas Southwestern Medical Center

OpenAlex ID: A5058555378

A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma

2020 · Vinay K Puduvalli, Jing Wu, et al. · Neuro-Oncology · 50

Rapid regulation of c-myc protooncogene expression by progesterone in the avian oviduct.

1988 · K L Fink, E D Wieben, et al. · Proceedings of the National Academy of Sciences · 46

A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium study

2000 · S. Clifford Schold, John G. Kuhn, et al. · Neuro-Oncology · 35

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial

2026 · Byram H. Ozer, Scott M. Lindhorst, et al. · medRxiv · 1

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial

2026 · Byram H Ozer, Adam L Cohen, et al. · Neuro-Oncology Advances

Anti-seizure drugs and cancer therapies: potential interactions and impact on treatment

2026 · Karen Fink, Emmanuel Mantilla, et al. · Elsevier eBooks

2026 · Vinay Puduvalli, Michael Youssef, et al. · Springer eBooks

Works count: 9

Citation count: 132

H-index: 3

I10-index: 3